HC Wainwright & Co. Reiterates Buy on Agile Therapeutics, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Oren Livnat reiterated a Buy rating on Agile Therapeutics (NASDAQ:AGRX) and maintained a $12 price target.
June 07, 2023 | 11:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Oren Livnat reiterated a Buy rating on Agile Therapeutics and maintained a $12 price target.
The reiteration of the Buy rating and maintenance of the $12 price target by HC Wainwright & Co. analyst Oren Livnat indicates a positive outlook for Agile Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100